Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
ITRM Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: November 23, 2025
Report Source: 2025 3rd Quarter Report
Iterum Therapeutics PLC. Stock Analysis ITRM
United States Health Care Nano Cap Report: Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Read More Iterum Therapeutics PLC (ITRM) Chart
Key Statistics of Iterum Therapeutics PLC (ITRM)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.04Volume
63.19KP/E Ratio (TTM)
-52 Week Range
Market Cap
8.87MAvg. Volume
67.48KDividend Yield
-Financial Metrics & Statements of Iterum Therapeutics PLC (ITRM)
FAQ's for Iterum Therapeutics PLC (ITRM)
- According to Musaffa’s Shariah screening methodology, Iterum Therapeutics PLC (ITRM) is currently classified as NOT HALAL as of November 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Iterum Therapeutics PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Iterum Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Iterum Therapeutics PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Iterum Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Iterum Therapeutics PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.